Vascular endothelial growth factor-A enhances indoleamine 2,3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferation

Memorias do Instituto Oswaldo Cruz

Volumn 109, Issue 1, 2014, Pages 70-79

  Marti, Luciana Cavalheiro ^a   Pavon, Lorena ^a   Severino, Patricia ^a   Sibov, Tatiana ^a   Guilhen, Daiane ^a   Moreira Filho, Carlos Alberto ^a,b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dendritic cell; Immune; Indoleamine pyrrole 2,3 dioxygenase; Lymphocytes; Tolerance; Vascular endothelial growth factor A

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; MEMBRANE ANTIGEN; VASCULOTROPIN A;

APOPTOSIS; BIOSYNTHESIS; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CULTURE TECHNIQUE; CYTOLOGY; DENDRITIC CELL; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; MONOCYTE; MONONUCLEAR CELL; NECROSIS; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ULTRASTRUCTURE;

ANTIGENS, SURFACE; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MONOCYTES; NECROSIS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893712607     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/0074-0276130252     Document Type: Article

References (40)

1. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI 2000. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6: 1755-1766.
2. Braun D, Longman RS, Albert ML 2005. A two-step induction of indoleamine 2,3-dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106: 2375-2381.
3. Broker LE, Kruyt FA, Giaccone G 2005. Cell death independent of caspases: a review. Clin Cancer Res 11: 3155-3162.
4. Chen W 2011. IDO: more than an enzyme. Nat Immunol 12: 809-811.
5. da Costa TB, Sardinha LR, Larocca R, Peron JP, Rizzo LV 2011. Allogeneic apoptotic thymocyte-stimulated dendritic cells expand functional regulatory T cells. Immunology 133: 123-132.
6. Dikov MM, Ohm JE, Ray N, Tchekneva EE, Burlison J, Moghanaki D, Nadaf S, Carbone DP 2005. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 174: 215-222.
7. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P 2006. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176: 6752-6761.
8. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP 1998. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92: 4150-4166.
9. Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, Figuredor CG 2000. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100: 575-585.
10. Grohmann U, Bronte V 2010. Control of immune response by amino acid metabolism. Immunol Rev 236: 243-264.
11. Henics T, Wheatley DN 1999. Cytoplasmic vacuolation, adaptation and cell death: a view on new perspectives and features. Biol Cell 91: 485-498.
12. Kadambi A, Carreira CM, Yun CO, Padera TP, Dolmans DE, Carmeliet P, Fukumura D, Jain RK 2001. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res 61: 2404-2408.
13. Katz JB, Muller AJ, Prendergast GC 2008. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 222: 206-221.
14. Krause P, Singer E, Darley PI, Klebensberger J, Groettrup M, Legler DF 2007. Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J Leukoc Biol 82: 1106-1114.
15. Kushwah R, Hu J 2010. Dendritic cell apoptosis: regulation of tolerance versus immunity. J Immunol 185: 795-802.
16. Lalier L, Pedelaborde F, Braud C, Menanteau J, Vallette FM, Olivier C 2011. Increase in intracellular PGE2 induces apoptosis in Baxexpressing colon cancer cell. BMC Cancer 11: 153.
17. Lan Z, Ge W, Arp J, Jiang J, Liu W, Gordon D, Healey D, de Benedette M, Nicolette C, Garcia B, Wang H 2010. Induction of kidney allograft tolerance by soluble CD83 associated with prevalence of tolerogenic dendritic cells and indoleamine 2,3-dioxygenase. Transplantation 90: 1286-1293.
18. Lanzinger M, Jürgens B, Hainz U, Dillinger B, Raberger J, Fuchs D, Heitger A 2012. Ambivalent effects of dendritic cells displaying prostaglandin E2-induced indoleamine 2,3-dioxygenase. Eur J Immunol 42: 1117-1128.
19. Laxmanan S, Robertson SW, Wang E, Lau JS, Briscoe DM, Mukhopadhyay D 2005. Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem Biophys Res Commun 334: 193-198.
20. Livak KJ, Schmittgen TD 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
21. Lorusso G, Rüegg C 2008. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130: 1091-1103.
22. Mellor AL, Munn DH 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4: 762-774.
23. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, Blay JY 1998. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92: 4778-4791.
24. Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H 2007. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother 56: 761-770.
25. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191-1193.
26. Nemeth ZH, Deitch EA, Davidson MT, Szabo C, Vizi ES, Hasko G 2004. Disruption of the actin cytoskeleton results in nuclear factor-kappaB activation and inflammatory mediator production in cultured human intestinal epithelial cells. J Cell Physiol 200: 71-81.
27. Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Grohmann U, Puccetti P 2008. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci 105: 20828-20833.
28. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, Gabrilovich DI 1998. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 160: 1224-1232.
29. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, Servillo G, Brunacci C, Calvitti M, Bicciato S, Mazza EM, Boon L, Grassi F, Fioretti MC, Fallarino F, Puccetti P, Grohmann U 2011. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 12: 870-878.
30. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L 2005. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310: 850-855.
31. Prechtel AT, Turza NM, Theodoridis AA, Steinkasserer A 2007. CD83 knockdown in monocyte-derived dendritic cells by small interfering RNA leads to a diminished T cell stimulation. J Immunol 178: 5454-5464.
32. Rieser C, Bock G, Klocker H, Bartsch G, Thurnher M 1997. Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med 186: 1603-1608.
33. Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH 2007. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 117: 2570-2582.
34. Steinman RM 2012. Decisions about dendritic cells: past, present and future. Annu Rev Immunol 30: 1-22.
35. Szabolcs P, Park KD, Marti L, Deoliveria D, Lee YA, Colvin MO, Kurzberg J 2004. Superior depletion of alloreactive T cells from peripheral blood stem cell and umbilical cord blood grafts by the combined use of trimetrexate and interleukin-2 immunotoxin. Biol Blood Marrow Transplant 10: 772-783.
36. Takahashi A, Kono K, Ichihara F, Sugai H, Fujii H, Matsumoto Y 2004. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immunother 53: 543-550.
37. Trinchieri G 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13: 251-276.
38. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, Toyoshima K, Seya T 2000. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors. Infect Immun 68: 6883-6890.
39. Wood KJ, Bushell AR, Jones ND 2010. The discovery of immunological tolerance: now more than just a laboratory solution. J Immunol 184: 3-4.
40. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G 2003. Intratumoral T cells, recurrence and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213.